ACRS Dividend: Aclaris Therapeutics Inc Yield Insights

Income

Balance sheet

Cash flow

Annual

Quarterly

ACRS Income

Financials in millions USD. Fiscal year is February - January.

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Revenue	15	18	31	29	6	6
Revenue Growth (YoY)	-44%	-42%	7%	383%	0%	50%
Cost of Revenue	15	15	18	11	4	5
Gross Profit	0	3	13	17	2	1
Selling, General & Admin	21	21	31	25	23	20
Research & Development	45	32	98	77	43	31
Operating Expenses	153	55	102	102	67	52
Other Non Operating Income (Expenses)	3	1	8	2	-1	0
Pretax Income	-141	-132	-88	-86	-90	-51
Income Tax Expense	--	0	0	0	0	0
Net Income	-141	-132	-88	-86	-90	-51
Net Income Growth	281%	50%	2%	-4%	76%	-68%
Shares Outstanding (Diluted)	122.61	77.29	69.8	65.21	56.73	42.54
Shares Change (YoY)	72%	11%	7%	15%	33%	3%
EPS (Diluted)	-1.15	-1.7	-1.26	-1.33	-1.6	-1.2
EPS Growth	121%	35%	-5%	-17%	33%	-69%
Free Cash Flow	-79	-56	-79	-68	-52	-39
Free Cash Flow Per Share	-0.64	-0.72	-1.13	-1.04	-0.91	-0.91
Gross Margin	0%	16.66%	41.93%	58.62%	33.33%	16.66%
Operating Margin	-1,019.99%	-288.88%	-287.09%	-293.1%	-1,083.33%	-833.33%
Profit Margin	-940%	-733.33%	-283.87%	-296.55%	-1,500%	-850%
Free Cash Flow Margin	-526.66%	-311.11%	-254.83%	-234.48%	-866.66%	-650%
EBITDA	-153	-52	-89	-85	-65	-49
EBITDA Margin	-1,019.99%	-288.88%	-287.09%	-293.1%	-1,083.33%	-816.66%
D&A For EBITDA	0	0	0	0	0	1
EBIT	-153	-52	-89	-85	-65	-50
EBIT Margin	-1,019.99%	-288.88%	-287.09%	-293.1%	-1,083.33%	-833.33%
Effective Tax Rate	--	0%	0%	0%	0%	0%